Osteosarcoma is the most common primary bone malignancy in children and adolescents. Although improvements in therapeutic strategies were achieved, the outcome remains poor for most patients with metastatic or recurrent osteosarcoma. Therefore, it is imperative to identify novel and effective prognostic biomarker and therapeutic targets for the disease. Long noncoding RNAs (lncRNAs) are a novel class of RNA molecules defined as transcripts >200 nucleotides that lack protein coding potential. Many lncRNAs are deregulated in cancer and are important regulators for malignancies. Nine lncRNAs (91H, BCAR4, FGFR3-AS1, HIF2PUT, HOTTIP, HULC, MALAT-1, TUG1, UCA1) are upregulated and considered oncogenic for osteosarcoma. Loc285194 and MEG3 are two lncRNAs downregulated and as tumor suppressor for the disease. Moreover, the expressions of LINC00161 and ODRUL are associated with chemo-resistance of osteosarcoma. The mechanisms for these lncRNAs in regulating development of osteosarcoma are diverse, e.g. ceRNA, Wnt/β-catenin pathway, etc. The lncRNAs identified may serve as potential biomarkers or therapeutic targets for osteosarcoma.
Introduction
The human transcriptome consists of protein-coding genes and non-coding RNAs (ncRNAs). Long non-coding RNAs (lncRNAs) are in the range from 200 nt to ~100 kb [1] . Most lncRNAs, like mRNAs, are transcribed by RNA polymerase II and are capped, polyadenylated, and spliced. A major difference between lncRNAs and mRNAs is that lncRNAs have little if any protein coding potential. Approximately 7,000-23,000 lncRNAs have been identified in vivo, which is significantly higher than the number of protein-coding genes [2] . In relationship with the nearest protein-coding genes, lncRNAs can be classified as (i) sense, (ii) antisense, (iii) bidirectional, (iv) intronic, and (v) intergenic [3] [4] [5] . LncRNAs in the cytoplasm may regulate the stability and the translation of mRNAs, act as the precursor of microRNAs (miRNA), or compete the endogenous RNAs (CeRNAs), regulate the distribution of miRNAs on their target. lncRNAs in the nucleus can act at epigenetic level and at genetic level through interacting with the transcription preinitiation complex at the promoter. [3, 4, [6] [7] [8] LncRNAs can positively or negatively regulate gene expression through multiple mechanisms. For epigenetic and transcription regulation, lncRNAs may recruit transcription factors or chromatin-modifying complexes to their DNA targets, form heterogeneous nuclear ribonucleoprotein (hnRNP) complexes, act as decoys to sequester RNA-binding proteins (RBPs) and microRNAs, or directly interact with RNAs and DNAs by base pairing. For posttranscriptional regulation, lncRNAs may regulate the stability and the translation of mRNAs, act as the precursor of microRNAs (miRNA), compete the endogenous RNAs (CeRNAs), or regulate the distribution of miRNAs on their target [3, 4, [6] [7] [8] (Fig. 1) .
Osteosarcoma is the most common type of highly malignant bone tumor in children and adolescents. It arises from mesenchymal cells and is pathologically characterized by spindle cells and aberrant osteoid formation [9, 10] . 80% of patients who do not have distant metastases at initial diagnosis will become long-term survivors. However, patients with metastatic or recurrent disease have less than 20% chance of long-term survival despite aggressive therapies [11] . Identification of clinically relevant biomarkers for prognosis is therefore urgently need for these patients. In the past few years, a number of potential molecular markers have been identified while specific diagnostic biomarker for osteosarcoma is not yet been confirmed [12] [13] [14] . Increasing evidences indicate that many of the genomic mutations in cancer reside in regions that do not encode proteins but are often transcribed into lncRNAs. Aberrant expression of lncRNAs is also associated with different cancer types [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . As discussed in the present review, lncRNAs play important role in the cellular function and transformation activity in osteosarcoma (Fig. 2) ; oncogenic lncRNA: 91H, BCAR4, FGFR3-AS1, HIF2PUT, HOTTIP, HULC, MALAT-1, TUG1, UCA1; tumor suppressor lncRNA: Loc285194, MEG3; drug associated lncRNA, LINC00161,ODRUL. These lncRNA may be potential biomarkers and therapeutic targets for the disease.
Oncogenic LncRNAs in Osteosarcoma

H19 antisense RNA (91H)
91H is located on the position of the H19/IGF2 locus with 119 kb in length. 91H was overexpressed in human breast cancer and was involved in the regulation of IGF2 expression [30] . Reduced 91H expression was also demonstrated in high-grade invasive esophageal squamous cell carcinoma and colorectal cancer. Knockdown of 91H inhibited the proliferation, migration, and invasiveness of colorectal cancer cells [31, 32] .
91H expression was notably increased in osteosarcoma patients and cell lines as compared to healthy controls and normal human bone cell lines. Elevated expression of 91H was significantly correlated with advanced clinical stage. Furthermore, 91H was an independent prognostic factor for overall survival in osteosarcoma patients after treatments. Knockdown of 91H inhibited osteosarcoma cells proliferation and promoted apoptosis in vitro [33] while the underlying mechanism is not clear.
Breast cancer antiestrogen resistance 4 (BCAR4)
BCAR4 was identified using functional genetic screens to isolate genes capable of inducing antiestrogen resistance in human breast cancer cells [34] . BCAR4 contributes to antiestrogen resistance and promotes breast cancer proliferation and metastasis through noncanonical Hedgehog/GLI2 pathway [35] [36] [37] .
BCAR4 is upregulated in osteosarcoma tissues and its overexpression correlated with poor prognosis of osteosarcoma patients. Knockdown of BCAR4 inhibited proliferation and migration of osteosarcoma cells in vitro and tumorigenesis and metastasis in vivo through GLI2 target genes. The oncogenic effect of BCAR4 in osteosarcoma is by activating GLI2-dependent gene transcription through direct promoter interaction [38] . The mechanism, however, differs from those found in breast cancer in which BCAR4 is associated with GLI2 in the protein complexes [39] .
FGFR3 antisense transcript 1 (FGFR3-AS1)
FGFR3-AS1, initially named as lncRNA-BX537709, is oriented in antisense direction and formed a 'tail-to-tail' pairing pattern with 1053 nt full complementarity to FGFR3. FGFR3-AS1 is first reported to be upregulated in osteosarcoma and is correlated with poor prognosis. The expression of FGFR3-AS1 and FGFR3 is positively correlated in osteosarcoma tissues. Knockdown of FGFR3-AS1 inhibited the proliferation and cell cycle progression of osteosarcoma cells in vitro. Moreover, knockdown of FGFR3-AS1 inhibited xenograft tumor growth of osteosarcoma cells in vivo. Through antisense pairing with FGFR3 3'UTR, FGFR3-AS1 increases mRNA stability and expression of FGFR3, a protein known to be important in cancer development [40, 41] .
HIF-2α promoter upstream transcript (HIF2PUT)
HIF2PUT, previously named as TCONS_00004241, is located on chromosome 2p21, on the antisense side of the promoter upstream region of a cancer-associated mRNA, hypoxiainducible factor-2α (HIF-2α) [42] [43] [44] . The lncRNA belongs to a class of lncRNAs known as promoter upstream transcripts (PROMPTs), that regulate the transcriptional activity of host genes [45, 46] . The expression of HIF2PUT was significantly correlated with HIF-2α in colorectal cancer tissues. Knockdown of HIF2PUT suppressed the expressions of HIF-2α and the stemness genes, OCT4, SOX2, and CD44. The knockdown also inhibited the cancer stem cells properties in colorectal cell lines, including proliferation, self-renewal, migration, and invasion abilities [42] . Compared with non-cancerous bone tissues, HIF-2α mRNA and HIF2PUT expressions were both significantly upregulated in osteosarcoma tissues. In addition, HIF2PUT expression levels were positively correlated with HIF-2α. Moreover, osteosarcoma patients with HIF-2α mRNA and/or HIF2PUT over-expression frequently had large tumor size, advanced clinical stage, positive distant metastasis, and shorter overall and disease-free survival. Overexpression of HIF2PUT markedly inhibited cell proliferation and migration, decreased the percentage of CD133 expressing cells, and impaired the osteosarcoma self-renewal of the osteosarcoma MG63 cells [43, 44] . However, the HIF2PUT/HIF-2α pathway is yet to be confirmed in osteosarcoma.
HOXA transcript at the distal tip (HOTTIP)
HOTTIP was previously considered as a negative prognostic factor in patients with liver cancer, gastric cancer, pancreatic cancer, non-small cell lung cancer, tongue squamous cell carcinoma, colorectal cancer [47] [48] [49] [50] [51] . Increased expression of HOTTIP was associated with enhanced cancer cell proliferation and metastasis. The action mechanism for HOTTIP is at least through regulating of (i) RNA-binding proteins (RBPs), e.g. WDR5/MLL complex; (ii) EMT bio-markers, e.g. E-cadherin, vimentin, snail 1, etc.; (iii) HOXA genes, e.g HOXA13 [52] . Inhibition of HOTTIP potentiated the antitumor effects of gemcitabine in vitro and in vivo [53] .
HOTTIP was overexpressed in osteosarcoma tissues compared with adjacent nontumorous tissues. Elevated HOTTIP expression was associated with an advanced clinical stage and distant metastasis. Additionally, knockdown of HOTTIP suppressed osteosarcoma cell proliferation, migration and invasion in vitro. Increased expression of HOTTIP was correlated with chemoresistance in osteosarcoma by activating the Wnt/β-catenin pathway [54, 55] .
Highly up-regulated in liver cancer (HULC)
HULC is located on chromosome 6p24.3. The HULC transcript is about 500 nt long, localizes to the cytoplasm and associates with ribosomes [56] . HULC was initially found to be strongly overexpressed in human hepatocellular carcinoma [56] [57] [58] , gastric cancer [59] , B-cell lymphoma [60] , colorectal cancer [61] , in which it serves as an oncogene.
HULC is capable of promoting tumor growth, migration, invasion, angiogenesis in hepatocellular carcinoma and colorectal cancer cells [61, 62] . The lncRNA acts as a miRNA sponge that binds to and reduces the expression of a number of miRNAs, including miR200a-3p, miR-107 [63, 64] . HULC promotes tumor angiogenesis in liver cancer through miR-107/E2F1/SPHK1 signaling [62] . It also suppresses miR-9 targeting of PPARA mRNA by eliciting methylation of CpG islands in the miR-9 promoter [63] .
HULC was significantly up-regulated in osteosarcoma tissues and cell lines compared with normal controls. Overexpression of HULC was correlated with clinical stage and distant metastasis. Moreover, elevated expression of HULC was associated with lower survival rates in osteosarcoma patients. Suppression of HULC decreased cell proliferation, migration, invasion in osteosarcoma while the underlying mechanism is still not known. [65] Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) MALAT-1 is also known as noncoding nuclear-enriched abundant transcript 2 (NEAT-2), a nuclear lncRNA with a length of 8.7 kb and located on chromosome 11q13 [66] . MALAT-1 was primarily identified in non-small cell lung cancer [66] . It was reported to be upregulated in lung, breast, pancreas, liver, colon, gastric, uterus, cervix and prostate cancers [67, 68] . MALAT1 may serve as an independent prognostic biomarker for the survival of these cancers [69, 70] .
MALAT-1 acts as a transcriptional regulator for genes including those involved in cell proliferation, migration and metastasis [66] . MALAT1 functions as ceRNAs and regulates RNA transcription through competitively binding to common miRNAs, such as, cell division cycle 42 (cdc42) via miR-1 in breast cancer cells [71] , MMP14 and Snail via miR-22 in human melanoma [72] , SLUG via miR-204 in lung adenocarcinoma [73] .
MALAT1 was significantly up-regulated in osteosarcoma tissues compared with paired non-tumor tissues. The expression of MALAT1 was remarkably associated with advanced clinical stage and distant metastasis of osteosarcoma patients [74] . Knockdown of MALAT1 inhibited the proliferation and invasion of human osteosarcoma cell and suppressed metastasis in vitro and in vivo. The expressions of PCNA, MMP-9, phosphorylated PI3Kp85α, and Akt were significantly reduced in MALAT1-deleted cells. MALAT1 might suppress the tumor growth and metastasis via PI3K/AKT signaling pathway [75] . Moreover, MALAT1 may also promote osteosarcoma development by acting as a ceRNA for miR376A to promote TGFA expression [76] .
Taurine upregulated gene 1 (TUG1)
TUG1 is a 7.1-kb gene located on chromosome 22q12.2. The lncRNA was first identified in a genomic scan for genes upregulated in response to taurine treatment in developing mouse retinal cells [77] . TUG1 is upregulated in various human cancers, such as hepatocellular carcinoma, glioma, bladder cancer, esophageal squamous cell carcinoma, gastric cancer, ovarian cancer, renal cell carcinoma [78] , but downregulated in non-small cell lung cancer and multiple myeloma [79, 80] .
TUG1 promotes cell proliferation, migration and invasion, and suppresses apoptosis in human ovarian cancer cells, bladder cells, colorectal cancer cells [81, 82] . TUG1 mediates its biological functions at least in part through alteration of the protein expression levels of apoptosis-related mediators in ovarian cancer, chromatin remodeling and sequestration of miRNAs, e.g. miR-26/PTEN in human glioma cells [83] , miR-145/ ZEB2 in bladder cancer cell [84] .
TUG1 was significantly overexpressed in the osteosarcoma tissues compared with matched adjacent normal tissues. Upregulation of TUG1 was strongly correlated with poor prognosis and was an independent prognostic indicator for overall survival [85] . TUG1 knockdown inhibited cell proliferation, induced G0/G1 cell cycle arrest and apoptosis in vitro, and suppressed tumor growth in vivo in osteosarcoma cells. TUG1 acted as an endogenous sponge to directly bind to miR-9-5p and downregulated miR-9-5p expression, leading to downregulation of POU2F1 and facilitating the tumorigenesis of osteosarcoma. [86] Urothelial Carcinoma Associated 1 (UCA1) UCA1, a 2314-bp lncRNA encoded on chromosome 19, was firstly identified in bladder cancer [87] . UCA1 expression was upregulated in many cancers, such as hepatocellular carcinoma, colorectal cancer, gastric cancer, esophageal squamous cell carcinoma and lung cancer [88] [89] [90] [91] [92] [93] . Recently, some studies have also reported the relevance of UCA1 in acquired resistance to drugs [87, 94, 95] . Meta-analysis of studies available from various databases, e.g. PubMed, showed a significant negative association between UCA1 levels and overall survival time in different cancers, such as colorectal cancer, non-small cell lung cancer, gastric cancer, and ovarian cancer. The analysis suggested that high expression level of UCA1 was associated with poor clinical outcome [87, 96] .
UCA1 was reported to regulate cell proliferation, invasion, apoptosis, and migration in various cancer. UCA1 promotes cancer cell proliferation by interacting with BRG1, hnRNP I, CREB or miR-216b. UCA1 increases drug resistance via SPRK1, Wnt6 and Wnt signaling pathway. Upregulation of UCA1 inhibits cell apoptosis via AKT-Bax-Bcl-2 signaling pathway. UCA1 promotes cancer metastasis by miR-216b-FGFR1-ERK signaling pathway [88, 97, 98] .
UCA1 expression was upregulated in osteosarcoma tissues and cell lines. High UCA1 expression was significantly correlated with large tumor size, high tumor grade, positive distant metastasis, and advanced clinical stage. UCA1 knockdown inhibited osteosarcoma cell proliferation, promoted cell apoptosis, and suppressed cell invasion and migration, whereas UCA1 overexpression showed opposite effects. The findings suggested that UCA1 may contribute to osteosarcoma initiation and progression, and would not only be a novel prognostic marker but also a potential therapeutic target for the disease [99] . However, the pathways identified in other cancers leading to biological effect of UCA1 are yet to be confirmed in osteosarcoma.
Tumor Suppressor LncRNA in Osteosarcoma
Loc285194
Loc285194, also called LSAMP antisense RNA 3, consists of 4 exons with 2105 nt in length and is located on chromosome 3q13.31 [100] . Recent studies showed that Loc285194 was down-regulated in several cancers such as esophageal squamous cell carcinoma, colorectal cancer, and plays key roles in tumor development and progression [101] . Loc285194 is a direct transcription target of p53 [102] . The lncRNA acts as a tumor suppressor in colon cancer cells, partly by repressing miR-211 through direct interaction. Moreover, miR-211 promotes cell growth, and at the same time, represses loc285194 expression through a reciprocal repression feedback loop [103] . chr3q13.31 is also named as osteo3q13.31, the region harbors frequent focal copy number alterations and loss of heterozygosity in primary osteosarcoma [100] . Loc285194 showed loss of expression in primary osteosarcoma samples and cell lines. Depletion of Loc285194 promoted proliferation of normal osteoblasts through regulation of apoptotic and cell cycle transcripts as well as VEGF receptor 1 [100] .
Maternally expressed gene 3 (MEG3)
MEG3 is an imprinted gene belonging to the imprinted DLK1-MEG3 locus located on chromosome 14q32.3 in humans [104] . The lncRNA is widely expressed in many human tissues but it is lost in many cancers due to hypermethylation at promoter or the intergenic region [105] . Reduced expression of MEG3 has been found in non-small cell lung cancer, bladder cancer, gastric cancer, colorectal cancer, breast cancer, prostate cancer and many other cancer tissues [106] [107] [108] [109] [110] [111] [112] .
Ectopic expression of MEG3 in esophageal squamous carcinoma cell, gastric cancer cell, non-small cell lung cancer cells inhibited cell proliferation, promoted apoptosis, and suppressed metastasis. MEG3 induces accumulation of p53 protein, stimulates the transcription of p53-dependent promoters, and selectively regulates p53 target gene expression, e.g. MDM2 [109, 110, 113] . Overexpression of MEG3 also influenced the activity of Wnt/β-catenin pathway in retinoblastoma cell lines [114] , and reduced the level of miR-21-5p expression in cervical cancer cells [115] .
The expression levels of MEG3 were significantly reduced in cisplatin-resistant A549/DDP lung cancer cells, compared with those in parental A549 cells. Furthermore, upregulation of MEG3 re-sensitized the A549/DDP cells to cisplatin in vitro. MEG3-mediated chemosensitivity enhancement was associated with the induction of cell-cycle arrest and increased apoptosis, through regulation of p53, β-catenin and survivin, a target gene of the Wnt/ β-catenin signaling pathway [107, 116] .{Bian, 2016, LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p}
In osteosarcoma, the expression of MEG3 was clearly lower in osteosarcoma tissues compared with adjacent non-tumor tissues, and was associated with clinical stage and distant metastasis (P<0.05). However, the role of MEG3 in osteosarcoma development is not yet clear.
Drug Associated LncRNA in Osteosarcoma
Long intergenic non-protein coding RNA 161 (LINC00161) LINC00161 is located on chromosome 21q21. LINC00161 was upregulated during cisplatin treatment in osteosarcoma cells. Overexpression of LINC00161 accelerated cisplatin-induced apoptosis and reduced chemoresistance in cells [117] . IFIT2, a target gene of miR-645 and a member of the IFN-induced gene family, promotes cancer apoptosis in oral squamous cell carcinoma [118] and in osteosarcoma cells [117] . Acting as a miR-645 sponge, LINC00161 increases IFIT2 protein level and thus promotes cell apoptosis in osteosarcoma cells [117] .
Osteosarcoma doxorubicin resistance-related up-regulated lncRNA (ODRUL)
ODRUL was revealed by lncRNA microarray to be the most up-regulated lncRNA in human osteosarcoma doxorubicin resistant cell line MG63/DXR than its paternal cell line MG63. ODRUL was confirmed subsequently to be elevated in different doxorubicin-resistant osteosarcoma cell lines and reduced in different doxorubicin-sensitive osteosarcoma cell lines. Moreover, ODRUL was increased in specimens of osteosarcoma patients with a poor chemoresponse and lung metastasis. Knockdown of ODRUL inhibited cell proliferation, migration, and partly reversed doxorubicin resistance in vitro in osteosarcoma cells. The expression of classical drug resistance-related ATP-binding cassette, subfamily B, member 1 (ABCB1) gene was decreased after the ODRUL knockdown [119] . The lncRNA may serve as a novel target for reversing doxorubicin resistance in osteosarcoma.
Future Perspectives
LncRNA as biomarker for osteosarcoma lncRNAs are involved in tumorigenesis, tumor cells proliferation, invasion, migration, apoptosis, and angiogenesis of osteosarcoma. They may be secreted and circulate in body fluids. The circulatory lncRNAs are strongly resistant to RNases and can be detected by PCR. Recent reports suggested that lncRNAs could be good candidates for tumor biomarkers and possessed high specificity, high sensitivity, and noninvasive characteristics [67, [120] [121] [122] [123] . LncRNA PCA3 is highly expressed in prostate cancer [124] . The detection of PCA3 in the urine has been demonstrated to be a more specific marker to diagnose prostate cancer than the commonly used prostate-specific antigen (PSA) and already found wide application in prostate cancer [125] [126] [127] . Similarly, UCA1 transcript detected in urine was shown to be a highly sensitive and specific biomarker of bladder carcinoma [128] . HULC was detected with high frequency in plasma of patients with hepatocellular carcinoma [57] . MALAT1 was detected in plasma as a biomarker for prostate cancer [129] . UCA1, HULC, MALAT1 are lncRNAs overexpressed in osteosarcoma. Therefore, it would be worthwhile to explore the potential use of these circulatory lncRNAs as biomarkers for osteosarcoma.
LncRNA as therapeutic target for osteosarcoma
LncRNAs play important role in the function and development of osteosarcoma, indicating they might be the potential therapeutic targets for treatment. lncRNA can be targeted by the use of small interfering RNA, antisense oligonucleotide, ribozyme, aptamer, miRNAs; such approaches have long been evaluated for targeting critical cancer-associated genes and they are in different phase of clinical trials [130] . Although therapy targeting lncRNAs is still in the infancy stage, further development in the way to target lncRNA for osteosarcoma treatment will likely be promising.
